% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pulte:154791,
      author       = {D. Pulte$^*$ and L. Jansen$^*$ and H. Brenner$^*$},
      title        = {{C}hanges in long term survival after diagnosis with common
                      hematologic malignancies in the early 21st century.},
      journal      = {Blood cancer journal},
      volume       = {10},
      number       = {5},
      issn         = {2044-5385},
      address      = {London [u.a.]},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2020-01029},
      pages        = {56},
      year         = {2020},
      note         = {#EA:C070#LA:C070#},
      abstract     = {Five-year survival has increased for many hematologic
                      malignancies in the 21st century. However, whether this has
                      translated into greater long-term survival is unknown. Here,
                      we examine 10- and 20-year survival for patients with
                      multiple myeloma (MM), acute lymphoblastic leukemia (ALL),
                      acute myeloblastic leukemia (AML), chronic lymphoid leukemia
                      (CLL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma
                      (NHL), and Hodgkin lymphoma (HL). Data were extracted from
                      the Surveillance, Epidemiology, and End Results-9 database.
                      Patients age 15+ with the above malignancies were included.
                      The newly developed boomerang method was used to examine 10-
                      and 20-year relative survival (RS) for patients in 2002-2006
                      and 2012-16. Ten and 20-year RS increased for each
                      malignancy examined, with increases ranging from $+4.4\%$
                      units for 20-year RS for AML to $+23.1\%$ units for 10-year
                      RS for CML. Ten year RS was $>50\%$ in 2012-16 for patients
                      with CLL, CML, HL, NHL, and DLBCL, at $77.1\%,$ $62.1\%,$
                      $63.9\%,$ $64.5\%,$ and $63.0\%,$ respectively. Survival
                      dropped between 10 and 20 years after diagnosis for most
                      malignancies. Long-term survival is increasing for common
                      hematologic malignancies, but late mortality is an ongoing
                      issue. Further study of long-term outcomes in curable
                      malignancies to determine the reason for these later
                      decreases in survival is indicated.},
      cin          = {C070 / C120 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32404891},
      doi          = {10.1038/s41408-020-0323-4},
      url          = {https://inrepo02.dkfz.de/record/154791},
}